Trial of drug for trauma patients includes victims of Iraqi violenceBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7552.1234-e (Published 25 May 2006) Cite this as: BMJ 2006;332:1234
- Owen Dyer
A major new trial will test a cheap, widely available drug that investigators hope could prevent tens of thousands of deaths from haemorrhage each year.
The trial, the clinical randomisation of an antifibrinolytic in significant haemorrhage (CRASH-2) trial, will test the effects of tranexamic acid (TXA), an antifibrinolytic, on mortality and need for transfusion among adult trauma patients with ongoing major haemorrhage or who have a significant risk of haemorrhage.
Among people aged between 5 years and 45 years worldwide trauma is second only to HIV and AIDS as a cause of death. Many of the three million patients …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial